Drug Development

Almac Group Appoints Two New Vice Presidents

Almac Group announced the appointment of two new vice presidents – Dr. John Robson (in the photo) and George Tiger – at its Craigavon and Souderton headquarter facilities, respectively.

John Robson

Packaging Companies Announce Merger to Form WestRock

WestRock Company was announced by MeadWestvaco Corporation and Rock-Tenn Company as the chosen name for the new venture when the two packaging companies complete their previously announced combination. 

Hovione, Ligand Collaborate on Captisol Drug Stability Product

Pharmaceutical packaging and manufacturing firms can use the product to help increase the stability of certain drugs.

Hovione today announced a co-promotion and collaboration agreement with Ligand to provide Hovione's customers efficient access to Captisol technology.

No votes yet

DFH Pharma, Hetero Group Partner on Developing Second-Generation HIV Maturation Inhibitor Drugs

The pharmaceutical firms are looking to develop treatments that block replication of the virus.

DFH Pharma, Inc., a privately held pharmaceutical company focused on the development of HIV therapeutics, announced that it has entered into a Research and Product Development Agreement with Hetero Group ("HETERO"), a privately held research-based global pharmaceutical group with headquarters in Hyderabad, Andhra Pradesh, India, to develop the next generation of HIV maturation inhibitor drugs.

No votes yet

Tris Pharma Attains Approval for Extended-release Oral Suspension Allergy Drug

The drug is indicated for seasonal and perennial allergic rhinitis in children ages two and up.

Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that the U.S. Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Karbinal™ ER (carbinoxamine maleate) Extended-release Oral Suspension 4mg/5ml, the first sustained-release histamine receptor blocking agent indicated for the treatment of seasonal and perennial allergic rhinitis in children ages 2 and up.

No votes yet

Bristol-Myers Squibb Funds Cancer Treatment Collaboration Grants

The company has donated a total of $175,000 to the American Cancer Society and Princeton HealthCare System to support cancer treatment and patient care.

Bristol-Myers Squibb has awarded grants totaling $175,000 to the American Cancer Society Eastern Division and Princeton HealthCare System (PHCS) to support comprehensive navigation services for patients with cancer both independently and as part of a collaborative effort among several hospitals in central New Jersey.

Your rating: None Average: 5 (1 vote)

Takeda Pharmaceuticals, Scripps Research Institute Expand Collaboration

The partnership is intended to identify potential new drugs and compounds for various diseases.

The Scripps Research Institute (TSRI) and the Takeda Pharmaceutical Company have announced plans to expand their recent research collaboration to search for new drug targets for a variety of diseases.

The new agreement extends an initial collaboration launched in 2010 between scientists on the Florida campus of TSRI and Envoy Therapeutics that led to several breakthroughs in identifying potential new compounds for neurological and psychiatric diseases. Envoy was acquired by Takeda Pharmaceuticals last November.

No votes yet

Tech Innovations Drive Growth in $60 Billion Drug Delivery Market

According to a recent report, new drug delivery methods are viewed by pharma firms and packaging partners as crucial growth generators.

The next generation of advanced pharmaceutical technologies could be poised to fuel remarkable growth in the $60 billion global drug delivery market, and Rainbow Biosciences—the biotech subsidiary of Rainbow Coral Corp. (OTCBB: RBCC)—plans to be right in the middle of the action.

No votes yet

HUYA Bioscience, Shanghai Zhangjiang Biotech Partner on Drug Development

The pharmaceutical development companies will work to bring new drug innovations into the global pipeline.

HUYA Bioscience International announced today a collaborative partnership with Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co., Ltd. and Shanghai Pharma Engine Co. Ltd. (collectively, "Zhangjiang Biotech Pharmaceutical Base").  HUYA is an international leader in accelerating the global development of China's pharmaceutical innovations.  This new partnership will focus on innovations coming out of companies located in Zhangjiang Biotech Pharmaceutical Base that could meet critical global pharmaceutical pipeline needs.

No votes yet

Cylene Pharmaceuticals Calls on TetraGene to Advance Anti-Cancer Technologies

The agreement is aimed to advance the ocmpany’s quadruplex-targeting technologies.

Cylene Pharmaceuticals, Inc. announced today that it has entered into an exclusive, worldwide Option and License Agreement that will allow TetraGene LLC to advance the development of Quarfloxin and Cylene's associated anticancer quadruplex-targeting technologies. Cylene will receive an upfront fee, as well as potential milestone payments and royalties on product sales for the exclusive license. 

No votes yet
Syndicate content